Darstein, F.; Hoppe-Lotichius, M.; Vollmar, J. et al.
Pretransplant coronary artery disease is a predictor for myocardial infarction and cardiac death after liver transplantationEUROPEAN JOURNAL OF INTERNAL MEDICINE. Bd. 51. 2018 S. 41-45
Schattenberg, J.; Schoennenbeck, U.; Marcus, W. et al.
Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD - the German CONSTANS STUDYJOURNAL OF HEPATOLOGY. Bd. 68. 2018 S. S830-S831
Vollmar, Johanna; Schmid, Julia C.; Hoppe-Lotichius, Maria et al.
Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantationa prospective single-center cohort studyTRANSPLANT INTERNATIONAL. Bd. 31. H. 11. 2018 S. 1207-1215
Labenz, C.; Baron, J. S.; Toenges, G. et al.
Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patientsALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 48. H. 3. 2018 S. 313-321
Buchler, Britta; Worns, Marcus-Alexander; Singer, Susanne
Psychological well-being in liver cancer patientsONKOLOGE. Bd. 24. H. 9. 2018 S. 725-730
Houcken, Juliane; Degenhart, Christina; Bender, Klaus et al.
PTPN22 and CTLA-4 Polymorphisms Are Associated With Polyglandular AutoimmunityJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. Bd. 103. H. 5. 2018 S. 1977-1984
Zhu, A. X.; Finn, R. S.; Galle, P. R. et al.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)ANNALS OF ONCOLOGY. Bd. 29. 2018 S. 208-208
Llovet, Josep M.; Kudo, Masatoshi; Finn, Richard et al.
Ramucirumab As Second-Line Treatment in Patients with Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following Sorafenib: Pooled Results from Two Global Phase 3 Studies (REACH-2 and REACH)HEPATOLOGY. Bd. 68. 2018 S. 166A-166A
Zhu, Andrew X.; Kang, Yoon-Koo; Yen, Chia-Jui et al.
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.JOURNAL OF CLINICAL ONCOLOGY. Bd. 36. H. 15. 2018
Buggisch, Peter; Vermehren, Johannes; Mauss, Stefan et al.
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis CJOURNAL OF HEPATOLOGY. Bd. 68. H. 4. 2018 S. 663-671